This study will compare the absolute and relative effectiveness of managing real-life asthma with and without the use of NIOX MINO® and NIOX Flex® to measure exhaled nitric oxide (eNO) as a marker of underlying airway inflammation to guide appropriate management. As exhaled nitric oxide responds rapidly to environmental changes and can act as a marker of underlying inflammation it is proposed that incorporating eNO monitoring into routine asthma management treatment allows strategies to be more accurately tailored to the patients needs, increasing the probability of good asthma control.
Study Type
OBSERVATIONAL
Enrollment
400
Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
Research in Real Life
Cambridge, United Kingdom
Severe Exacerbation Rate
Where exacerbations are defined as an occurrence of: Unscheduled hospital admissions / Emergency Room attendance for asthma, OR Use of acute courses of oral steroids
Time frame: One Year Outcome Period
Proxy Asthma Control
1. No recorded hospital attendance for asthma, including admission, Emergency Room (ER) attendance or Out-Patient Department (OPD) attendance, AND 2. No prescriptions for acute courses of oral steroids, AND 3. No GP consultations, hospital admissions or ER attendance for lower respiratory tract infections (LRTI) requiring antibiotics.
Time frame: One year outcome period
Asthma Control (including SABA)
Proxy asthma control (defined above), including the absence of average daily prescribed dose of ≤200mcg salubtamol / ≤500mcg terbutaline
Time frame: One year outcome
Respiratory-related hospitalisations and referrals
Mean number of respiratory-related hospitalisations and referrals per patient during the outcome year
Time frame: One year outcome period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.